Stoke's therapy for Dravet syndrome employs a unique "upregulation" mechanism. Instead of knocking out a faulty gene or delivering a new one, its ASO targets the existing healthy gene to produce more of the needed NAV1.1 protein. This approach is specifically designed for haploinsufficient diseases where one gene copy is functional but insufficient.

For drug-resistant childhood epilepsy, the ketogenic diet is a primary medical treatment. It works by switching the brain's fuel source from glucose to ketones, a process that acts like a hard reset for brain function, calming erratic neural activity.

The ketogenic diet has a profound neuropharmacological effect, acting as a brain stabilizer. It reduces levels of the excitatory neurotransmitter glutamate while increasing the main inhibitory neurotransmitter, GABA. This quieting effect explains its efficacy in treating epilepsy and anxiety.

Stoke highlights its Open Label Extension (OLE) study as a critical asset. It provides rare longitudinal data, now approaching four years, demonstrating that patients with Dravet syndrome get progressively better "year on top of year." This continuous "gain of function" is a powerful piece of evidence for regulators, clinicians, and investors.

In epilepsy treatment, patients often use the ketogenic diet for only 2-5 years. The fact that seizures frequently do not return after stopping the diet suggests it can induce lasting metabolic repairs and heal brain dysfunction, rather than just managing symptoms temporarily.

A significant number of medications prescribed for mental illness are also used to treat epilepsy. This overlap suggests that mental disorders and seizure conditions share underlying biological mechanisms, opening the door for non-pharmacological epilepsy treatments like the ketogenic diet to be applied to psychiatry.

While outsiders assume walking is the ultimate recovery goal, NervGen's research reveals that regaining hand function for daily tasks like eating or using a computer is the most vital improvement for patient independence. This highlights the importance of patient-defined quality-of-life endpoints in clinical trials.

The success of Praxis's small molecule for a genetic epilepsy presents a strategic alternative to cell and gene therapies. In an era where complex modalities face funding, safety, and commercial hurdles, advanced small molecules offer a viable and potentially more practical path for treating genetic disorders.

The company's clinical trials go beyond standard pain scores to track improvements in function, sleep, and patient satisfaction. Demonstrating that patients can climb stairs, drive, and sleep better provides a more compelling value proposition for a faster return to normal life, resonating with patients, surgeons, and payers alike.